Please ensure Javascript is enabled for purposes of website accessibility

NexImmune finishes $23 million Series A round (access required)

A Gaithersburg biopharmaceutical company has raised $23 million in Series A financing, the company announced Tuesday. NexImmune raised the money in a round co-led by ArrowMark Partners and Barer & Son, along with participation from Piedmont Capital Partners. ArrowMark is a new investor while Barer & Son had already invested in NexImmune. “NexImmune has developed a very practical, ...

To purchase a reprint of this article, contact [email protected].